Home
Search
Study Topics
Glossary
|
|
|
|
|
|
Sponsors and Collaborators: |
Massachusetts General Hospital Stanley Medical Research Institute |
---|---|
Information provided by: | Massachusetts General Hospital |
ClinicalTrials.gov Identifier: | NCT00289861 |
We propose a double-blind, placebo-controlled trial to study the effectiveness and tolerability of adding risperidone to stable yet only partially remitted patients with schizophrenia maintained on clozapine.
Condition | Intervention | Phase |
---|---|---|
Schizophrenia |
Drug: Risperidone |
Phase IV |
Study Type: | Interventional |
Study Design: | Treatment, Randomized, Double-Blind, Placebo Control, Parallel Assignment, Efficacy Study |
Official Title: | Risperidone Augmentation in Patients With Schizophrenia Partially Responsive to Clozapine |
Estimated Enrollment: | 40 |
Study Start Date: | February 2003 |
Study Completion Date: | October 2006 |
Ages Eligible for Study: | 18 Years to 65 Years |
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
Exclusion Criteria:
United States, Massachusetts | |
Massachusetts General Hospital | |
Boston, Massachusetts, United States, 02114 |
Principal Investigator: | Oliver Freudenreich, M.D. | MGH |
Principal Investigator: | Donald C Goff, M.D. | MGH |
Study ID Numbers: | 2002-P-000584 |
Study First Received: | February 8, 2006 |
Last Updated: | April 23, 2007 |
ClinicalTrials.gov Identifier: | NCT00289861 |
Health Authority: | United States: Food and Drug Administration |
Schizophrenia risperidone prolactin clozapine |
Schizophrenia Dopamine Mental Disorders Clozapine |
Risperidone Psychotic Disorders Serotonin Schizophrenia and Disorders with Psychotic Features |
Neurotransmitter Agents Tranquilizing Agents Molecular Mechanisms of Pharmacological Action Physiological Effects of Drugs Psychotropic Drugs Central Nervous System Depressants Dopamine Antagonists |
Antipsychotic Agents Pharmacologic Actions Serotonin Antagonists Serotonin Agents Therapeutic Uses Dopamine Agents Central Nervous System Agents |